Johnson & Johnson Advances Neuropsychiatry...

By HEOR Staff Writer

May 12, 2026

Neuropsychiatry treatment innovations continue to reshape care for complex conditions. At the recent APA and ASCP meetings, Johnson & Johnson presented new portfolio and pipeline data focused on major depressive disorder, treatment-re...
Breakthrough in Biocatalysis: Advancing Oral PCSK9 Inhibitors
FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases
MFN Drug Pricing Savings: Projected $593 Billion in U.S. Healthcare Savings O...
Navigating the Challenges of Patient-Centered AI Systems in Postpartum Depres...
JNJ-4804 IBD Therapy Proves Effective for Refractory Inflammatory Bowel Disease
Amgen Financial Results: Q1 2026 Performance Breakdown
Gaps in AI Governance Healthcare Frameworks: Ensuring Effective Implementatio...
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometab...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced...
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Mar...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...